Insights
Independent analysis of company developments, industry trends, and capital markets, with a focus on undercovered public companies. We examine what changed, why it matters, and the implications for investors.
Topics
88 insights
Biotechnology & HealthcareMirum’s Atebrioz Approval Shows Why a Missed Primary Endpoint Does Not Always End a Drug Program
FDA approved Atebrioz for fibrodysplasia ossificans progressiva after a 63-patient trial in which a closely watched lesion-incidence endpoint failed to reach conventional statistical significance. The approval highlights the importance of effect size, endpoint selection and totality of evidence, but for Mirum the commercial question may be harder than the regulatory one.
Biotechnology & HealthcareNeuroSense’s PrimeC Has Built a Stronger ALS Data Package, but Financing Is Now the Critical Variable
NeuroSense Therapeutics is targeting a Canadian filing for PrimeC in December while exploring a potentially smaller U.S. pivotal program and an accelerated-approval pathway. The clinical dataset has strengthened materially, but with only $0.23 million of cash reported at June 30, the investment case increasingly depends on whether the company can convert its regulatory progress into financing, partnership support, or a more capital-efficient route to approval.
Mining & Critical MineralsCritical Minerals Are Forcing Aerospace to Rethink Materials, but Substitution Has Limits
Aerospace suppliers are testing alternatives to rare-earth-dependent coatings as China’s dominance in critical-mineral production and processing keeps supply-chain risk elevated. Substitution can reduce exposure in selected applications, but it does not solve the wider problem of concentrated refining and component supply.
Market CommentaryAI Gold Rush: Inside the Multi-Trillion-Dollar AI Arms Race With No Clear Payoff (Yet)
With tech giants pouring billions into chips, data centers, and power grids despite unclear returns. Is the payoff coming, or is this a high-stakes gamble?